Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-resistant Peritoneal Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06434610
What this trial is testing

B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Who this might be right for
Platinum-resistant Recurrent Ovarian Cancer
Shanghai Jiaolian Drug Research and Development Co., Ltd 90
Testing effectiveness (Phase 2)Study completedNCT02659384
What this trial is testing

Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
European Organisation for Research and Treatment of Cancer - EORTC 122
Testing effectiveness (Phase 2)Looking for participantsNCT05985655
What this trial is testing

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic AdenocarcinomaNon-small Cell Lung Cancer (NSCLC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 230
Large-scale testing (Phase 3)UnknownNCT05622890
What this trial is testing

A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer

Who this might be right for
Epithelial Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT05271318
What this trial is testing

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

Who this might be right for
Platinum-refractory Ovarian CarcinomaPlatinum-resistant Ovarian CancerPlatinum-Resistant Fallopian Tube Carcinoma+6 more
TILT Biotherapeutics Ltd. 29
Testing effectiveness (Phase 2)Looking for participantsNCT05579366
What this trial is testing

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Who this might be right for
High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more
Genmab 884
Testing effectiveness (Phase 2)UnknownNCT02188550
What this trial is testing

Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer

Who this might be right for
Ovarian CancerEndometrial Cancer
Sinai Hospital of Baltimore 20
Early research (Phase 1)Study completedNCT00059618
What this trial is testing

PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
M.D. Anderson Cancer Center 21
Large-scale testing (Phase 3)Study completedNCT04209855
What this trial is testing

Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

Who this might be right for
Epithelial Ovarian CancerPeritoneal CancerFallopian Tube Cancer
AbbVie 453
Testing effectiveness (Phase 2)Study completedNCT00003523
What this trial is testing

Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum

Who this might be right for
Ovarian CancerPrimary Peritoneal Cavity Cancer
Gynecologic Oncology Group
Testing effectiveness (Phase 2)Active Not RecruitingNCT05446298
What this trial is testing

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

Who this might be right for
Ovarian CancerHigh Grade Serous Adenocarcinoma of OvaryPrimary Peritoneal Carcinoma+1 more
OncoC4, Inc. 58
Testing effectiveness (Phase 2)Looking for participantsNCT06730347
What this trial is testing

Lorigerlimab in Participants With Advanced Solid Tumors

Who this might be right for
Platinum-resistant Ovarian CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+8 more
MacroGenics 80
Testing effectiveness (Phase 2)Ended earlyNCT01681368
What this trial is testing

Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer

Who this might be right for
Epithelial Ovarian CancerPeritoneal NeoplasmsFallopian Tube Neoplasms
National Cancer Institute (NCI) 11
Early research (Phase 1)Study completedNCT00692900
What this trial is testing

Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer

Who this might be right for
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
University of Pittsburgh 25
Testing effectiveness (Phase 2)Study completedNCT02889900
What this trial is testing

Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer

Who this might be right for
Recurrent Platinum Resistant Ovarian Cancer
AstraZeneca 62
Early research (Phase 1)Study completedNCT05483933
What this trial is testing

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Who this might be right for
Platinum-resistant Ovarian CancerFallopian Tube CancerEpithelial Ovarian Cancer+4 more
Shattuck Labs, Inc. 86
Testing effectiveness (Phase 2)Study completedNCT07648745
What this trial is testing

Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer

Who this might be right for
Bowel ObstructionOvarian CancerFallopian Tube Cancer+1 more
Prof Gordon Jayson 30
Testing effectiveness (Phase 2)Study completedNCT03657043
What this trial is testing

Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Seagen Inc. 98
Testing effectiveness (Phase 2)Study completedNCT03206047
What this trial is testing

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Platinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+3 more
National Cancer Institute (NCI) 12
Early research (Phase 1)Looking for participantsNCT06856499
What this trial is testing

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

Who this might be right for
Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
University of Colorado, Denver 50
Next Page